Stress-induced Antibiotic Susceptibility Testing on a Chip
January 8th, 2014
5.9K views
We have developed a microfluidic platform for rapid antibiotic susceptibility testing. Fluid is passed at high speeds over bacteria immobilized on the bottom of a microfluidic channel. In the presence of stress and antibiotic, susceptible strains of bacteria die rapidly. However, resistant bacteria can survive these stressful conditions.
Overview
This study presents a microfluidic platform designed for rapid antibiotic susceptibility testing of bacteria. By immobilizing bacteria in a microfluidic channel and applying antibiotics under stress conditions, the method allows for quick assessment of bacterial viability.
Key Study Components
Area of Science
- Microfluidics
- Antibiotic susceptibility testing
- Cell viability assessment
Background
- Traditional methods for testing antibiotic susceptibility can be time-consuming.
- Microfluidic technologies offer advantages in speed and efficiency.
- Understanding bacterial responses to antibiotics is crucial for effective treatment.
- This method eliminates the need for monitoring bacterial division.
Purpose of Study
- To develop a rapid method for determining bacterial susceptibility to antibiotics.
- To assess bacterial viability under stress conditions.
- To improve upon existing susceptibility testing techniques.
Methods Used
- Immobilization of log phase bacteria in a microfluidic channel.
- Application of antibiotic and fluorescent stains under high flow rates.
- Automated collection of phase contrast and fluorescence images.
- Calculation of normalized bacterial death percentages over time.
Main Results
- Susceptible bacteria show rapid cell death in the presence of antibiotics.
- Resistant bacteria can survive under stressful conditions.
- Normalized death percentages provide insights into antibiotic susceptibility.
- The method allows for real-time monitoring of bacterial viability.
Conclusions
- The microfluidic platform offers a rapid alternative to traditional susceptibility testing.
- This approach enhances the understanding of bacterial responses to antibiotics.
- Future applications may include broader testing of various bacterial strains.
Frequently Asked Questions
What is the main advantage of this microfluidic method?
It allows for rapid assessment of antibiotic susceptibility without needing to monitor bacterial division.
How are bacterial responses monitored in this study?
Bacterial viability is monitored using phase contrast and fluorescence imaging techniques.
What types of bacteria can be tested using this method?
The method can be applied to various strains of bacteria, particularly those of clinical interest.
How does the flow rate affect the experiment?
High flow rates stress the bacteria, activating their antibiotic-targeted biochemical pathways.
What is the significance of calculating normalized death percentages?
Normalized death percentages help quantify the effectiveness of the antibiotic over time.
Can this method be used for other types of assays?
While primarily designed for antibiotic susceptibility testing, the platform may be adapted for other assays involving bacterial responses.
Executive Industry Relevance
This microfluidic platform addresses a critical bottleneck in antibiotic development by eliminating the need for bacterial growth monitoring during susceptibility testing. By enabling rapid, stress-activated phenotypic assessment, the method supports faster go/no-go decisions in lead optimization and reduces late-stage attrition due to unexpected resistance mechanisms. The approach enhances predictive confidence in early discovery by providing quantitative, time-resolved viability data under controlled mechanical and biochemical stress.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of antibiotic-targeted biochemical pathways under stress to validate target engagement and mechanism of action.
- Operational Value: Provides rapid phenotypic readouts that de-risk target hypotheses by linking compound exposure to bacterial death kinetics.
Screening & Assay Development
- Scientific Value: Generates quantitative, normalized death percentage metrics that support assay standardization and hit confirmation in antimicrobial screens.
- Operational Value: Facilitates multiplexed, automated testing of compounds against immobilized bacterial populations, improving throughput and reproducibility.
Translational & Preclinical Research
- Scientific Value: Supports disease-relevant testing by allowing repeated drug exposure cycles on the same bacterial population, mimicking pharmacokinetic fluctuations.
- Operational Value: Enables longitudinal monitoring of resistance development and adaptive responses in preclinical models.
Pipeline & Workflow Integration
The method fits within the antimicrobial discovery continuum from target validation through lead identification, offering a bridge between biochemical screening and phenotypic confirmation by delivering functional susceptibility data without proliferation-dependent readouts.
- Discovery Biology: Supports hypothesis testing of antibiotic mechanism by correlating stress-induced pathway activation with compound-specific killing kinetics.
- Screening: Delivers assay-ready, standardized bacterial monolayers with quantitative fluorescence-based viability readouts compatible with automated imaging platforms.
- Analytics: Enables calculation of normalized death percentages over time, providing a quantitative metric for comparing compound potency and susceptibility profiles across strains.
- Translational Research: Connects to preclinical work by allowing repeated antibiotic exposure cycles, supporting PK/PD modeling and resistance evolution studies.
- Enterprise Reuse: The microfluidic platform is designed for repeated use with interchangeable antibiotic solutions, positioning it as a reusable screening asset rather than a single-use assay.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in antibiotic efficacy by providing direct, real-time visualization of stress-enhanced susceptibility.
- Operational Value: Reduces assay time from days to under two hours, accelerating screening cycles and enabling rapid iteration in medicinal chemistry.
- Strategic Value: Improves capital efficiency by minimizing false positives in early screening through direct phenotypic confirmation of target-mediated killing.
- Portfolio Impact: Supports risk-adjusted prioritization by identifying compounds that demonstrate rapid, stress-dependent killing of susceptible strains while sparing resistant controls.
Implementation Considerations
- Requires expertise in microfluidic device assembly, bacterial culture, and fluorescence microscopy.
- Depends on access to syringe pumps, inverted microscopes with automated stage control, and image processing software for bacterial counting.
- Necessitates standardization of flow rates, antibiotic concentrations, and stress-inducing enzyme preparations across users and labs.
- Requires adaptation of bacterial immobilization protocols for different species or strain-specific adhesion properties.
- Practical limitations include potential biofilm formation under sustained shear stress and variability in epoxy-coated slide binding efficiency, which may affect reproducibility.
Biopharma FAQs
Why does stress activation improve antibiotic susceptibility testing?
Stress activation accelerates antibiotic-targeted biochemical pathways, making susceptible bacteria die faster under flow and antibiotic exposure. This eliminates the need to wait for bacterial division as a proxy for viability, enabling rapid phenotypic readouts within minutes rather than hours or days.
How does immobilizing bacteria in a microfluidic channel support target validation?
Immobilization allows repeated exposure to antibiotics and stress conditions on the same bacterial population, enabling direct observation of target engagement through time-resolved death kinetics. This supports mechanistic de-risking by linking compound presence to pathway-specific killing without growth-dependent confounders.
What does measuring normalized bacterial death percentage enable in drug discovery?
Normalizing fluorescence-based dead cell counts to phase contrast total cell counts provides a quantitative, time-dependent metric of antibiotic efficacy that corrects for variations in bacterial loading and imaging conditions. This enables accurate comparison of susceptibility profiles across strains and compounds in screening campaigns.
Why are replication requirements important for cross-functional collaboration?
Replication ensures that observed susceptibility differences between strains are consistent across experiments, reducing false positives from stochastic binding or imaging artifacts. This supports reliable data sharing between discovery, screening, and preclinical teams by establishing assay robustness and inter-user reproducibility.
What statistical analysis is required before implementing this method in a screening pipeline?
Implementation requires establishing baseline death rates for resistant strains and defining significant increase thresholds for susceptible strains over time, typically using normalized death percentage trajectories. Teams must define acceptable variability limits and statistical power for detecting compound-specific effects in multiplexed formats.
Chapters in this video
0:05
Title
1:40
Making the Poly(dimethylsiloxane) (PDMS) Layer
2:29
Assembling the Flow Cell
3:41
Loading the Bacterial Suspension
5:08
Loading the Solutions
6:15
Image Acquisition
8:02
Disinfecting the Flow Cell and Counting the Bacteria
9:21
Results: Representative Bacterial Susceptibility Imaging and Survival Data
12:07
Conclusion
